Testosterone Enanthate Overdose and Accidental Excess Dose: What to Do

How Testosterone Enanthate Works in the Body

Testosterone enanthate is an esterified prodrug. After intramuscular injection, the enanthate ester undergoes hydrolysis by tissue and plasma esterases, releasing free testosterone into the systemic circulation over several days. This slow-release pharmacokinetic profile is the reason prescribers space injections one to four weeks apart.

Receptor Binding and Downstream Effects

Free testosterone binds androgen receptors (AR) in skeletal muscle, bone marrow, liver, brain, and reproductive tissues. The AR-testosterone complex translocates to the nucleus, where it acts as a transcription factor for genes governing protein synthesis, erythropoiesis, and sexual differentiation [2]. A second pathway involves conversion to dihydrotestosterone (DHT) via 5-alpha reductase and to estradiol via aromatase. Both metabolites carry independent clinical effects: DHT drives prostate and hair-follicle signaling, while estradiol influences bone density and lipid metabolism.

Why the Mechanism Matters in Overdose

Supraphysiologic testosterone concentrations amplify every downstream signal. Erythropoietin production rises, pushing hematocrit toward dangerous levels. Aromatization to estradiol increases, producing gynecomastia and fluid retention. Negative feedback suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which can cause testicular atrophy and azoospermia even from a short period of excess dosing [3]. Understanding these pathways explains why "more testosterone" does not mean "better outcomes."

Recognizing an Overdose or Accidental Excess Dose

Most accidental excess exposures happen one of three ways: a patient forgets they already injected this week and injects again, a pharmacy compounds a vial at a higher concentration than expected, or an unsupervised user deliberately takes supraphysiologic doses. The clinical picture depends on whether the excess is acute (one-time) or chronic (weeks to months).

Acute Single Excess Dose

A single double-dose (e.g., 400 mg instead of 200 mg) typically produces no immediate dramatic symptoms. Over the following 48 to 96 hours, patients may notice oily skin, mild acne flare, increased libido, irritability, or a sense of restlessness. These resolve as the depot clears. The FDA-approved prescribing information for testosterone enanthate states that "there is one report of acute overdosage by injection of testosterone enanthate: testosterone levels of up to 11,400 ng/dL were implicated in a cerebrovascular accident" [4].

Chronic Supraphysiologic Exposure

Repeated excess dosing over weeks produces a different and far more dangerous profile. Polycythemia is the most common serious complication: the T-Trials (N=790 men aged 65+) observed that even standard-dose testosterone gel raised hematocrit above 54% in a clinically meaningful subset [1]. The Endocrine Society's 2018 clinical practice guideline recommends checking hematocrit at baseline, 3 to 6 months after initiation, and then annually, with dose reduction or phlebotomy if hematocrit exceeds 54% [5]. At supraphysiologic doses, this threshold can be crossed within 4 to 8 weeks.

Other chronic overdose signs include:

• Severe cystic acne (back, shoulders, face)
• Sleep apnea onset or worsening
• Gynecomastia from elevated aromatization
• Peripheral edema from sodium and water retention
• Mood volatility, aggression, or hypomania
• Elevated liver enzymes (AST, ALT), rarely progressing to peliosis hepatis

Polycythemia: The Most Dangerous Complication

Polycythemia is the single biggest acute-risk factor in testosterone overdose. Hematocrit above 54% thickens blood, increasing the probability of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction.

How Testosterone Drives Red Cell Overproduction

Testosterone stimulates erythropoiesis through at least two mechanisms: direct stimulation of erythroid progenitor cells in bone marrow and increased renal erythropoietin secretion [6]. A 2014 dose-response study in healthy men aged 18 to 50 demonstrated that hemoglobin and hematocrit rose in a linear, dose-dependent fashion across testosterone doses from 25 mg to 600 mg weekly, with the 600 mg group showing mean hematocrit increases of 7.2 percentage points above baseline at 20 weeks [7].

Management of Polycythemia

If hematocrit exceeds 54%, the Endocrine Society guideline recommends:

1. Stop or reduce the testosterone dose immediately
2. Perform therapeutic phlebotomy (removal of 1 unit, approximately 450 mL of whole blood)
3. Recheck hematocrit in 2 to 4 weeks
4. Do not resume full-dose TRT until hematocrit falls below 50%

Patients who present to an emergency department with hematocrit above 60% may require urgent phlebotomy and IV hydration to prevent thrombotic events [5].

Cardiovascular Risks of Supraphysiologic Testosterone

The relationship between testosterone and cardiovascular events has been studied extensively, with results that shift depending on dose and patient population.

What the Major Trials Show

The Testosterone Trials (TTrials) enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and randomized them to transdermal testosterone gel or placebo for 12 months [1]. The cardiovascular substudy using coronary CT angiography found that testosterone-treated men had a significantly greater increase in noncalcified coronary artery plaque volume compared with placebo (P = 0.003) [8]. This finding prompted an FDA-required label update in 2015 warning of possible increased cardiovascular risk.

The TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and established or high risk for cardiovascular disease) found that testosterone replacement did not significantly increase the incidence of major adverse cardiovascular events (MACE) over a median follow-up of 33 months (hazard ratio 0.99; 95% CI, 0.81 to 1.21) [9]. The key distinction: TRAVERSE used standard replacement doses targeting mid-normal levels, not supraphysiologic exposure.

Extrapolating to Overdose

No randomized trial has studied deliberate supraphysiologic dosing for cardiovascular outcomes, for obvious ethical reasons. Case reports and retrospective cohort data from androgen-abusing populations link chronic supraphysiologic testosterone to left ventricular hypertrophy, cardiomyopathy, and sudden cardiac death [10]. A 2019 systematic review in Circulation: Heart Failure identified 23 published cases of cardiomyopathy linked to anabolic steroid misuse, with a mean age at presentation of 30 years [10].

Hepatic and Metabolic Consequences

The liver metabolizes testosterone enanthate, and sustained high-dose exposure can produce hepatotoxicity.

Liver Injury Patterns

Oral 17-alpha-alkylated androgens (like methyltestosterone) carry the highest hepatotoxicity risk, but injectable testosterone enanthate is not entirely benign at supraphysiologic doses. Case reports document cholestatic jaundice and peliosis hepatis (blood-filled hepatic cysts) in patients using high-dose injectable testosterone for prolonged periods [4]. The NIH LiverTox database classifies testosterone and its esters as having a "likelihood score" of Category B for drug-induced liver injury [11].

Dyslipidemia

Excess testosterone suppresses HDL cholesterol in a dose-dependent fashion. In a controlled dose-response study, 600 mg/week testosterone enanthate reduced HDL by approximately 21% over 20 weeks [7]. Since low HDL is an independent cardiovascular risk factor, this effect compounds the vascular risks described above.

Reproductive and Endocrine Fallout

Even a brief period of supraphysiologic testosterone exposure can suppress the hypothalamic-pituitary-gonadal (HPG) axis for months.

Spermatogenesis Suppression

Exogenous testosterone suppresses intratesticular testosterone concentrations (which need to be 50 to 100 times higher than serum levels for normal spermatogenesis) by shutting down LH secretion. A WHO contraceptive efficacy trial demonstrated that weekly 200 mg testosterone enanthate injections suppressed sperm counts to azoospermia in 65% of men within 6 months [12]. Recovery of spermatogenesis after discontinuation took a median of 3.7 months, but in some men exceeded 12 months.

Testicular Atrophy

With LH and FSH driven to near-zero levels, Leydig and Sertoli cell stimulation ceases. Testicular volume measurably decreases within 8 to 12 weeks of supraphysiologic dosing. This is partially reversible after cessation, though full recovery depends on duration and dose of exposure.

Acute Management Protocol

There is no specific antidote for testosterone enanthate overdose. Management is supportive and complication-directed.

Immediate Steps After an Accidental Double-Dose

1. Do not attempt to "extract" the injection. The oil depot cannot be aspirated once injected intramuscularly.
2. Skip the next scheduled injection. With a half-life of approximately 4.5 days, the excess will clear over the following 2 to 3 weeks.
3. Monitor for symptoms: headache, visual changes, chest pain, calf swelling, shortness of breath.
4. Schedule a hematocrit check within 5 to 7 days.
5. Contact your prescribing physician to document the event and adjust the dosing calendar.

When to Go to the Emergency Department

Seek immediate medical evaluation if any of these occur:

• Chest pain or pressure
• Sudden onset severe headache or neurological deficits (possible stroke)
• Unilateral leg swelling, warmth, or redness (possible DVT)
• Shortness of breath with pleuritic chest pain (possible PE)
• Priapism (erection lasting >4 hours)

Management of Chronic Supraphysiologic Exposure

For patients presenting after weeks to months of excess dosing:

• Obtain stat hematocrit, comprehensive metabolic panel, lipid panel, and hepatic function tests
• Perform therapeutic phlebotomy if hematocrit exceeds 54%
• Obtain PSA (prostate-specific antigen) as supraphysiologic androgens may accelerate occult prostate pathology
• Consider echocardiography if the patient reports exertional dyspnea or has used supraphysiologic doses for over 6 months
• Refer to endocrinology for HPG axis recovery assessment including LH, FSH, and semen analysis at 3 and 6 months post-cessation

The Endocrine Society guideline states: "Clinicians should aim to achieve testosterone concentrations in the mid-normal range (450 to 600 ng/dL) during treatment, and should monitor hematocrit, PSA, and liver function to detect androgen-related adverse effects early" [5].

Prevention: Avoiding Accidental Excess

Most accidental overdoses are preventable with simple systems.

Practical Safeguards

• Use a medication tracking app or paper log. Record every injection date, dose, and injection site.
• Pre-fill syringes only for the current dose. Do not pre-fill multiple syringes and store them.
• Verify vial concentration each time. Testosterone enanthate is available in 200 mg/mL and 250 mg/mL concentrations; switching brands without adjusting volume is a common error.
• Set a phone alarm for injection day. If the alarm did not fire this week, you have not injected.

For prescribers, the 2018 Endocrine Society guideline recommends testosterone enanthate 75 to 100 mg weekly or 150 to 200 mg every 2 weeks as the standard intramuscular regimen [5]. Doses exceeding 200 mg weekly should prompt clinical justification and closer monitoring.

Long-Term Monitoring After an Overdose Event

After any documented overdose or period of supraphysiologic exposure, follow-up should include:

• Hematocrit at 1 month, 3 months, and 6 months post-event
• Lipid panel at 3 months (HDL recovery may lag)
• LH and FSH at 3 months to assess HPG axis recovery
• PSA at 3 and 12 months
• Liver enzymes if baseline values were elevated
• Semen analysis at 6 months if fertility is a concern

A hematocrit that remains above 50% at 3 months without ongoing testosterone use warrants evaluation for secondary polycythemia from other causes (obstructive sleep apnea, chronic hypoxia, myeloproliferative disorders) [5].